NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Breast Cancer Therapy



Women switched to anastrozole treatment have improved event-free survival



December 15th, 2005

Women switched to anastrozole treatment after initial tamoxifen treatment have improved event-free survival.

According to researchers from Austria, "Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy."

R. Jakesz and colleagues "investigated whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole. They presented a combined analysis of...


Source: Women's Health Weekly (2005-12-15)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login